CYP2D6 News and Research

RSS

Pharmacogenomics holds promise for personalized dementia therapies

Pharmacogenomics-based studies in the research for personalized therapeutics for dementia

8 Nov 2023

AMP releases consensus recommendations for CYP3A4 and CYP3A5 genotyping assays

The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical CYP3A4 and CYP3A5 genotyping assays, promote standardization of testing across different laboratories, and improve patient care.

10 Jul 2023

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

Researchers compiled evidence-based recommendations in consultation with European and North American clinicians and pharmacologists for recognizing and managing drug-drug interactions with nirmatrelvir–ritonavir.

3 Mar 2022

AMP’s new consensus can promote standardization of PGx gene/allele testing, improve patient care

The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical CYP2D6 assays, promote standardization of testing across different laboratories and improve patient care

11 Jun 2021

Interaction between antidepressants and opioid pain medication contributes to lesser pain relief

Common antidepressants interact with the opioid pain medication tramadol to make it less effective for pain relief, according to a study from University Hospitals.

26 Jun 2019

Scientists discover new drug target for chemically induced Parkinson's disease

More than three decades ago, scientists discovered that a chemical found in a synthetic opioid, MPTP, induced the onset of a form of Parkinson's disease.

23 Jun 2019

Initial gene analysis could result in more effective antipsychotic treatment

An initial gene analysis may yield better outcomes when patients are treated with the antipsychotic drugs risperidone and aripiprazole.

16 Apr 2019

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Study highlights need for population-specific precision medicine programs in Latin America

Drug safety and effectiveness vary greatly among populations worldwide. Genetics is one of the factors that contribute to variability in drug response.

3 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

New clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy

An international group of clinicians and scientists representing the Clinical Pharmacogenetics Implementation Consortium published the first-ever clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy in Clinical Pharmacology and Therapeutics.

1 Feb 2018

New drug shows promise to treat women with estrogen positive metastatic breast cancer

Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer in women with metastatic disease.

31 Aug 2017

Licorice could pose health risk by interacting with medications

Licorice roots have a diverse and flavorful history, having been used in ancient Egyptian times as a tea and in traditional Chinese medicines, all the way to today as a flavoring agent and as an ingredient in some licorice candies.

21 Aug 2017

Mayo Clinic highlights potential merits of individualizing treatment for patients taking antidepressants

Mayo Clinic is highlighting the potential merits of using precision medicine in prescribing antidepressants. Details appear in the current issue of Mayo Clinic Proceedings.

21 Jun 2016

Study reveals why anti-hormone therapy tamoxifen works better in some women than others

The anti-hormone therapy tamoxifen can reduce breast cancer recurrence by about half in women with hormone-sensitive breast cancer. But it works better in some women than others. Researchers are not sure why.

11 Dec 2015

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy.

9 Oct 2015

Concert Pharmaceuticals’ precision deuteration platform can enhance metabolic properties of drugs

Substituting deuterium for certain hydrogen atoms in molecules has been shown to enhance the metabolic properties of a number of drugs and provides a promising approach to the discovery and development of innovative drug products.

2 Jul 2015

GeneSight test better predicts antidepressant outcomes for patients with depression

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the individual genes that comprise the test, according to a peer-reviewed analysis by investigators from the Mayo Clinic and Assurex Health, and published online by The Pharmacogenomics Journal.

5 Mar 2015

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity, a Mayo Clinic study has found. The findings indicate that Z-endoxifen, co-developed by Mayo Clinic Cancer Center and the National Cancer Institute, may provide a new and better treatment for some women with estrogen positive breast cancer and, in particular, for those women who do not respond to tamoxifen and aromatase inhibitors.

13 Dec 2013

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all.

27 Nov 2013